Pay in 4 interest-free payments of $5.29 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Reconstitution: 3.0 mL per 50 mg vial (16.67 mg/mL) provides practical unit measurements
A pharmaceutical formulation comprising: an effective amount of cagrilintide and semaglutide, more than 10% w/v and less than 22% w/v, such as 10-20% w/v cyclodextrin of the hydroxypropyl-substituted alpha and/or beta type, said cyclodextrin comprising a minimum of about 0.4 and a maximum of about 1.0 hydroxypropyls per glucose unit, such as 0.58-1 .0 hydroxypropyls per glucose unit, about 3-30 mM histidine, about 10-40 mg/ml sorbitol, up to 2.0 mg/ml, such as up to 1 .5 mg/ml polysorbate 20 and/or 80, about 75-90% w/w water and having a pH of 5.6-6.0
Injections should be performed with the correct needle size to ensure a smooth and comfortable experience
For DSIP alone, we spent several days exploring the literature to pinpoint the peptides most conclusive therapeutic uses and the studies supporting its use toward those ends
